정지헌 (성균관대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회160

성균관대학교 의과대학

CV File 215 kb

J. Nanobiotechnol., Nov 30 2024, 22 (1) | https://doi.org/10.1186/s12951-024-03004-3 Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates

Linh Nguyen¹, Tiep Tien Nguyen^1*, Ju‑Yeon Kim^1* and Jee‑Heon Jeong^1*

¹Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Gyeonggi 16419, Republic of Korea.

^*Correspondence: Tiep Tien Nguyen, Ju‑Yeon Kim, Jee‑Heon Jeong

Abstract

Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment.

논문정보

형식Review Paper
게재일2024년 11월 (BRIC 등록일 2024-12-02)
연구진국내 연구진
분야 의약학 > 약학

댓글 작성 로그인

CV 열람하기

연락처 보기